← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #886 OF 1,000 MOST-CITED

Name and address on summary

FDA cited this observation 16 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation16
BY FISCAL YEAR
FY20261
FY20255
FY20241
FY20231
FY20222
FY20212
FY20192
FY20181
FY20171

How FDA worded it — real examples

The summary of records for HCT/Ps did not contain the address of the establishment that made the donor-eligibility determination.

Lucina Egg Bank · San Diego, California · Human Tissue for Transplantation · 2026-04-10

The summary of records for HCT/Ps did not contain the address of the establishment that made the donor-eligibility determination.

Elite IVF & Fertility Solutions LLC · Odessa, Texas · Human Tissue for Transplantation · 2025-03-28

The summary of records for HCT/Ps did not contain the address of the establishment that made the donor-eligibility determination.

Pacific Reproductive Center Inc · Corona, California · Human Tissue for Transplantation · 2025-03-12

The summary of records for HCT/Ps did not contain the name and address of the establishment that made the donor-eligibility determination.

InVia Fertility Specialists, PLLC · Hoffman Estates, Illinois · Human Tissue for Transplantation · 2025-02-05

The summary of records for HCT/Ps did not contain the address of the establishment that made the donor-eligibility determination.

Pacific Reproductive Center, Inc. · Torrance, California · Human Tissue for Transplantation · 2025-01-13

The summary of records for HCT/Ps did not contain the address of the establishment that made the donor-eligibility determination.

Innovative Fertility Center · Manhattan Beach, California · Human Tissue for Transplantation · 2024-12-17

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →